Audio Evolution Diagnostics v. USPTO — Supreme Court Petition Denied
Audio Evolution Diagnostics petitioned the U.S. Supreme Court to review a dispute with the USPTO over two medical audio patents covering physiological sound acquisition and processing apparatus. The Court denied the petition after just 130 days, leaving the underlying administrative determination intact and exhausting Audio Evolution’s federal appellate options.
Supreme Court shuts door on medical audio patent challenge in 130 days
Audio Evolution Diagnostics filed a petition for a writ of certiorari with the U.S. Supreme Court on January 27, 2025, challenging the United States Patent and Trademark Office over two patents: US8870791B2 and US8920343B2. These patents cover apparatus for acquiring and processing physiological auditory signals — technology with direct relevance to auscultation, remote diagnostics, and digital stethoscope-adjacent medical devices. The case was docketed as No. 24-806 and assigned to the District of Columbia circuit.
The Supreme Court denied the petition on June 6, 2025, just 130 days after filing. The basis of termination is recorded as ‘Petition Dismissed,’ with a verdict of ‘Petition DENIED.’ A denial of certiorari carries no precedential weight on the merits — the Court’s refusal to hear the case does not constitute an endorsement or rejection of the USPTO’s underlying position. However, as a practical matter, it leaves the administrative outcome undisturbed and forecloses further federal review for Audio Evolution at this level.
The speed of the denial — below the typical cert cycle — suggests the petition may not have presented the kind of circuit split or substantial federal question the Court typically requires for review. What drove the USPTO’s original determination, and whether Audio Evolution pursued inter partes review or ex parte reexamination at any stage, remains unclear from the public docket. The company’s next potential avenue, if any, would be limited to extraordinary procedural remedies or legislative channels.
Filing to Petition Dismissed in 130 days
130 days from filing to denial — faster than the median cert petition cycle of ~180 days
Supreme Court denies cert: what the ruling means for both parties
Certiorari denied — no merits ruling from the Court
A denial of certiorari means the Supreme Court declined to exercise its discretionary jurisdiction to hear the case. Critically, this is not a ruling on the merits. The Court issues no opinion, makes no finding on the validity or invalidity of the patents, and does not endorse the USPTO’s position. The lower administrative determination simply stands — undisturbed but not judicially validated.
No precedential effectAudio Evolution exhausts federal judicial review path
With certiorari denied, Audio Evolution Diagnostics has no further avenue for federal court review of the USPTO determination at issue. The patents US8870791B2 and US8920343B2 remain in whatever state the administrative proceeding left them. If claims were cancelled or narrowed, that outcome is now final absent extraordinary relief. The company’s enforcement position on any surviving claims may be weakened by the prolonged dispute history.
Federal review exhaustedUSPTO’s position stands — administrative determination preserved
The USPTO, represented by the Solicitor General, successfully defended against Supreme Court review. The agency’s underlying determination — whether a rejection, cancellation, or other administrative action — is now final from a federal judicial standpoint. This outcome is consistent with the Court’s historically low cert grant rate (~1–2%), but it does reinforce the finality of USPTO administrative proceedings when petitioners cannot demonstrate a compelling federal question.
Agency determination finalMedical audio IP enforcement landscape tightened
For companies operating in physiological sound monitoring, digital auscultation, and remote diagnostics, this outcome suggests the patent claims at issue will not receive Supreme Court clarification. Competitors and licensees in this space face reduced uncertainty about challenge pathways, but innovators seeking to enforce similar audio-physiological apparatus patents should note the difficulty of sustaining broad claims through USPTO review and federal appellate scrutiny.
Sector IP risk clarifiedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Audio Evolution Diagnostics | Individual | Medical audio diagnostics company — holder of US8870791B2 and US8920343B2Search in Eureka ↗ |
| Defendant | United States and Trademark Office | Individual | U.S. federal agency responsible for patent examination and administrative patent decisionsSearch in Eureka ↗ |
| Plaintiff counsel | Peter Joseph Corcoran | Attorney | Counsel for Audio Evolution DiagnosticsSearch in Eureka ↗ |
| Plaintiff law firm | Corcoran IP Law PLLC | Law Firm | Representing Audio Evolution DiagnosticsSearch in Eureka ↗ |
| Defendant counsel | D. John Sauer | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Defendant law firm | Solicitor General, United States Department of Justice | Law Firm | Representing United States and Trademark OfficeSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | U.S. Supreme CourtSearch in Eureka ↗ |
Official order — verbatim text
The Supreme Court’s ‘Petition DENIED’ disposition carries a precise legal meaning that is frequently misunderstood: it is not a ruling on the merits of Audio Evolution’s patent claims or the USPTO’s administrative determination. The Court exercised its discretionary jurisdiction to decline review, which requires agreement from four Justices. The speed of the denial — 130 days — and the absence of any noted dissent or call for the views of the Solicitor General suggests the petition did not raise a question the Court considered cert-worthy under Rule 10. The underlying USPTO outcome therefore stands as administratively final.
US8870791B2 & US8920343B2 — Physiological auditory signal apparatus
US8870791B2 (application no. US13/430561) and US8920343B2 (application no. US11/602017) cover apparatus-level inventions in the physiological audio signal domain — encompassing the hardware and signal processing systems used to capture, process, and in one case transmit sounds generated by the human body. These patents sit at the intersection of medical device engineering and digital signal processing, with direct applicability to electronic stethoscopes, cardiac monitoring, pulmonary diagnostics, and telehealth auscultation platforms.
Strategically, apparatus patents in the physiological audio space represent foundational IP for companies building next-generation remote diagnostics hardware. The fact that these patents were disputed through USPTO administrative proceedings and ultimately reached the Supreme Court — even if denied — indicates that competitors or the USPTO itself identified claim scope concerns. Any company designing physiological sound acquisition hardware should map its architecture against the surviving claims of these two patents, particularly given the rapid growth of AI-assisted auscultation and wearable biosignal capture devices.
Should you run an FTO against US8870791B2 and US8920343B2?
If your organisation develops, manufactures, or commercialises apparatus for capturing or processing body sounds — including electronic stethoscopes, pulmonary monitoring devices, cardiac acoustic sensors, or telehealth auscultation tools — these two patents warrant a formal freedom-to-operate assessment. The dispute history and Supreme Court petition suggest the claim boundaries were actively contested; understanding what claims survived, and in what form, is essential before product launch or investment.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to run structured prior art and claim-mapping analysis against US8870791B2 and US8920343B2 in minutes. Upload your product specification, and Eureka identifies claim overlap, flags prosecution history estoppel, and surfaces design-around opportunities — giving your team a defensible FTO basis before entering the physiological audio diagnostics market.
Run a freedom-to-operate analysis on US8870791B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent cases involving physiological audio and medical device IP
Explore comparable U.S. Supreme Court and Federal Circuit cases involving medical audio apparatus patents, USPTO administrative review challenges, and physiological signal IP disputes.
What this case signals for the medical audio diagnostics IP landscape
The Supreme Court’s swift denial highlights the finality of USPTO administrative proceedings and the narrow window for judicial intervention in patent office determinations.
Cert denial reinforces USPTO administrative finality in patent disputes
When the Supreme Court declines review this quickly, it typically signals the petition lacked a circuit split or substantial unresolved federal question. Patent owners facing adverse USPTO determinations should treat administrative proceedings — ex parte, IPR, or PGR — as effectively final and plan prosecution strategy accordingly.
Medical audio apparatus patents face heightened USPTO scrutiny
The involvement of two apparatus patents covering physiological sound acquisition and processing suggests claim scope was contested at the administrative level. R&D teams developing stethoscope, auscultation, or remote diagnostics hardware should conduct FTO analysis against US8870791B2 and US8920343B2 to assess surviving claim scope post-dispute.
Diagnostics v United — key questions answered
The denial means the Supreme Court declined to review the case on the merits. It is not a ruling on patent validity or the correctness of the USPTO’s decision. The underlying administrative determination stands as final, and Audio Evolution has exhausted its federal judicial review options at this stage.
Two patents were involved: US8870791B2 (application US13/430561) covering apparatus for acquiring and processing physiological auditory signals, and US8920343B2 (application US11/602017) covering apparatus for acquiring, processing and transmitting physiological sounds. Both relate to medical audio signal hardware.
The 130-day resolution is below the median cert petition cycle. While the public record does not specify the Court’s reasoning — cert denials carry no opinion — the speed is consistent with cases that do not present a circuit split, novel constitutional question, or issue of substantial federal importance under Supreme Court Rule 10.
These patents cover core apparatus for physiological sound capture and processing — technology directly relevant to electronic stethoscopes, remote auscultation platforms, and AI-assisted cardiac and pulmonary diagnostics. Companies in these segments should assess surviving claim scope post-dispute before commercialising competing hardware designs.
Federal judicial review is exhausted at this level. Extraordinary remedies such as a petition for rehearing are available but rarely succeed after a cert denial. Other potential avenues could include reexamination proceedings before the USPTO if new prior art is identified, or legislative channels — though none are indicated in the public record.
PatSnap Eureka searches patents and litigation data to answer instantly.